Matrix metalloproteinase 2 and 9 activity in patients with colorectal cancer liver metastasis

British Journal of Surgery

Volumn 90, Issue 12, 2003, Pages 1556-1564

  Waas, E T ^a   Wobbes, T ^a   Lomme, R M L M ^a   DeGroot, J ^b   Ruers, T ^a   Hendriks, T ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ENZYME PRECURSOR; GELATIN; GELATINASE A; GELATINASE B; TISSUE EXTRACT;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL FEATURE; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME ACTIVITY; FLUOROMETRY; HUMAN; HUMAN TISSUE; LIVER METASTASIS; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; QUANTITATIVE ASSAY; RISK ASSESSMENT; RISK FACTOR; ZYMOGRAPHY;

COLORECTAL NEOPLASMS; HUMANS; LIVER NEOPLASMS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9;

EID: 0348041947     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1002/bjs.4346     Document Type: Article

References (25)

1. Fong Y, Salo J. Surgical therapy of hepatic colorectal metastasis. Semin Oncol 1999; 26: 514-523.
2. Yamada H, Kondo S, Okushiba S, Morikawa T, Katoh H. Analysis of predictive factors for recurrence after hepatectomy for colorectal liver metastases. World J Surg 2001; 25: 1129-1133.
3. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997; 89: 1260-1270.
4. Zeng ZS, Huang Y, Cohen AM, Guillem JG. Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. J Clin Oncol 1996; 14: 3133-3140.
5. Musso O, Theret N, Campion JP, Turlin B, Milani S, Grappone C et al. In situ detection of matrix metalloproteinase-2 (MMP2) and the metalloproteinase inhibitor TIMP2 transcripts in human primary hepatocellular carcinoma and in liver metastasis. J Hepatol 1997; 26: 593-605.
6. Shimizu S, Nishikawa Y, Kuroda K, Takagi S, Kozaki K, Hyuga S et al. Involvement of transforming growth factor beta1 in autocrine enhancement of gelatinase B secretion by murine metastatic colon carcinoma cells. Cancer Res 1996; 56: 3366-3370.
7. Waas ET, Lomme RM, DeGroot J, Wobbes T, Hendriks T. Tissue levels of active matrix metalloproteinase-2 and -9 in colorectal cancer. Br J Cancer 2002; 86: 1876-1883.
8. Brand K, Baker AH, Perez-Canto A, Possling A, Sacharjat M, Geheeb M et al. Treatment of colorectal liver metastases by adenoviral transfer of tissue inhibitor of metalloproteinases-2 into the liver tissue. Cancer Res 2000; 60: 5723-5730.
9. Zeng ZS, Cohen AM, Zhang ZF, Stetler Stevenson W, Guillem JG. Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlates with lymph node and distant metastases. Clin Cancer Res 1995; 1: 899-906.
10. Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 2001; 93: 178-193.
11. Theret N, Musso O, Campion JP, Turlin B, Loreal O, L'Helgoualc'h A et al. Overexpression of matrix metalloproteinase-2 and tissue inhibitor of matrix metalloproteinase-2 in liver from patients with gastrointestinal adenocarcinoma and no detectable metastasis. Int J Cancer 1997; 74: 426-432.
12. Zeng ZS, Guillem JG. Distinct pattern of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 mRNA expression in human colorectal cancer and liver metastases. Br J Cancer 1995; 72: 575-582.
13. Zeng ZS, Guillem JG. Unique activation of matrix metalloproteinase-9 within human liver metastasis from colorectal cancer. Br J Cancer 1998; 78: 349-353.
14. Karakiulakis G, Papanikolaou C, Jankovic SM, Aletras A, Papakonstantinou E, Vretou E et al. Increased type IV collagen-degrading activity in metastases originating from primary tumors of the human colon. Invasion Metastasis 1997; 17: 158-168.
15. Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie. Cancer 1996; 77: 1254-1262.
16. Heussen C, Dowdle EB. Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal Biochem 1980; 102: 196-202.
17. DeGroot J, Verzijl N, Wenting-Van-Wijk MJG, Bank RA, Lafeber FPJG, Bijlsma JWJ et al. Age-related decrease in susceptibility of human articular cartilage to matrix metalloproteinase-mediated degradation: the role of advanced glycation end products. Arthritis Rheum 2001; 44: 2562-2571.
18. Beekman B, Drijfhout JW, Ronday HK, TeKoppele JM. Fluorogenic MMP activity assay for plasma including MMPs complexed to alpha 2-macroglobulin. Ann N Y Acad Sci 1999; 878: 150-158.
19. Kjeldsen L, Johnsen AH, Sengelov H, Borregaard N. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem 1993; 268: 10425-10432.
20. Ambiru S, Miyazaki M, Nakagawa K, Nakajima N. Increased serum type IV collagen 7-S levels in patients with hepatic metastasis. Am J Gastroenterol 1995; 90: 783-787.
21. Collins HM, Morris TM, Watson SA. Spectrum of matrix metalloproteinase expression in primary and metastatic colon cancer: relationship to the tissue inhibitors of metalloproteinases and membrane type-1-matrix metalloproteinase. Br J Cancer 2001; 84: 1664-1670.
22. Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol 2000; 10: 415-433.
23. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994; 370: 61-65.
24. Segain JP, Harb J, Grégoire M, Meflah K, Menanteau J. Induction of fibroblast gelatinase B expression by direct contact with cell lines derived from primary tumor but not from metastases. Cancer Res 1996; 56: 5506-5512.
25. Nakagoe T, Sawai T, Ayabe H, Nakazaki T, Ishikaw H, Hatano K et al. Prognostic value of carcinoembryonic antigen (CEA) in tumor tissue of patients with colorectal cancer. Anticancer Res 2001; 21: 3031-3036.